Pantoprazolo Hikma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazolo Hikma, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑oesophageal reflux disease, erosive oesophagitis and Zollinger‑Ellison syndrome in adult patients.

GNH USA supplies Pantoprazolo Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring EU‑standard quality for global distribution.

Pantoprazolo Hikma, a proton pump inhibitor, is used to manage acid‑related gastrointestinal disorders.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing gastric acid production. - Erosive oesophagitis: promotes healing of acid‑induced esophageal lesions. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - NSAID‑induced ulcer prophylaxis: helps prevent gastric ulcers in patients receiving long‑term non‑steroidal anti‑inflammatory drugs.

Pantoprazolo Hikma may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile infection - Low magnesium (hypomagnesemia) - Elevated liver enzymes - Interstitial nephritis - Stevens‑Johnson syndrome

When prescribing Pantoprazolo Hikma, clinicians should consider several precautionary measures to ensure safe use. - Renal function assessment: adjust use in patients with severe renal impairment. - Magnesium monitoring: periodic checks are advised during long‑term therapy. - Hepatic impairment caution: use with care in patients with liver disease. - CYP2C19 interaction awareness: consider potential reduced efficacy with certain enzyme inhibitors. - Discontinuation strategy: avoid abrupt cessation after prolonged use to prevent rebound acid hypersecretion. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazolo Hikma can affect the pharmacokinetics of several medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Atazanavir and other HIV protease inhibitors: reduced absorption leading to loss of antiviral effect. - Clopidogrel: decreased activation, potentially reducing antiplatelet activity. - Methotrexate (high‑dose): increased serum levels, raising toxicity risk. - Digoxin: enhanced serum concentration, may require dose adjustment. - Warfarin (some reports): potential alteration of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Omeprazole and other CYP2C19 inhibitors: may increase pantoprazole levels. - Rifampin and other CYP3A4 inducers: may decrease pantoprazole exposure. - Antifungal agents such as ketoconazole: possible increased plasma concentrations. - Antiretroviral efavirenz: may modestly reduce pantoprazole efficacy. - Diuretics (e.g., furosemide): risk of hypomagnesemia when combined long‑term.